Literature DB >> 23279671

New developments in the area of factor XIII.

V Schroeder1, H P Kohler.   

Abstract

Coagulation factor (F)XIII is best known for its role in fibrin stabilization and cross-linking of antifibrinolytic proteins to the fibrin clot. From patients with congenital FXIII deficiency, it is known that FXIII also has important functions in wound healing and maintaining pregnancy. Over the last decade more and more research groups with different backgrounds have studied FXIII and have unveiled putative novel functions for FXIII. FXIII, with its unique role as a transglutaminase among the other serine protease coagulation factors, is now recognized as a multifunctional protein involved in regulatory mechanisms and construction and repair processes beyond hemostasis with possible implications in many areas of medicine. The aim of this review was to give an overview of exciting novel findings and to highlight the remarkable diversity of functions attributed to FXIII. Of course, more research into the underlying mechanisms and (patho-)physiological relevance of the many described functions of FXIII is needed. It will be exciting to observe future developments in this area and to see if and how these interesting findings may be translated into clinical practice in the future.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23279671     DOI: 10.1111/jth.12074

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  28 in total

1.  Factor XIII and adipocyte biology.

Authors:  Deane F Mosher
Journal:  Blood       Date:  2014-08-21       Impact factor: 22.113

2.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

Review 3.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

4.  Ethacrynic acid is an inhibitor of human factor XIIIa.

Authors:  Srabani Kar; Kayla Vu; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-01       Impact factor: 2.605

5.  Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes.

Authors:  Christoffer Soendergaard; Peter Helding Kvist; Jakob Benedict Seidelin; Hermann Pelzer; Ole Haagen Nielsen
Journal:  J Gastroenterol       Date:  2015-12-11       Impact factor: 7.527

6.  Factor XIII B subunit polymorphisms and the risk of coronary artery disease.

Authors:  Zoltán A Mezei; Zsuzsanna Bereczky; Éva Katona; Réka Gindele; Emília Balogh; Szilvia Fiatal; László Balogh; István Czuriga; Róza Ádány; István Édes; László Muszbek
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

7.  Impaired Activity of Blood Coagulant Factor XIII in Patients with Necrotizing Enterocolitis.

Authors:  Guo-Zhong Tao; Bo Liu; Rong Zhang; Gigi Liu; Fizan Abdullah; Mary Cay Harris; Mary L Brandt; Richard A Ehrenkranz; Corinna Bowers; Camilia R Martin; R Lawrence Moss; Karl G Sylvester
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

8.  Effects of Factor XIII Deficiency on Thromboelastography. Thromboelastography with Calcium and Streptokinase Addition is more Sensitive than Solubility Tests.

Authors:  M Martinuzzo; L Barrera; D Altuna; F Tisi Baña; J Bieti; Q Amigo; M D'Adamo; M S López; J Oyhamburu; J C Otaso
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-08-16       Impact factor: 2.576

9.  Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.

Authors:  Felix Carl Fabian Schmitt; Maik von der Forst; Wolfgang Miesbach; Sebastian Casu; Markus Alexander Weigand; Sonja Alesci
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

10.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.